PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Immunogenetics. Author manuscript; available in PMC 2011 December 1.
Published in final edited form as:
PMCID: PMC3043355
NIHMSID: NIHMS261558

HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer

Abstract

Inherited genetic polymorphisms within immune response genes have been shown to associate with risk of invasive cervical cancer (ICC) and its immediate precursor, cervical intraepithelial neoplasia grade 3. Here, we used the transmission/disequilibrium test to detect disease-liability alleles and investigate haplotype transmission of KIR and HLA class I polymorphisms in a large family-based population of women with cervical cancer and their biological parents (359 trios). The effect of distinct human papillomavirus types was also explored. HLA-Cw group 1 (HLA-Cw alleles with asparagine at position 80), which serves as ligand for certain killer immunoglobulin-like receptors (KIR), was significantly overtransmitted in women with ICC (P=0.04), and particularly in the subgroup of women infected with high risk HPV16 or 18 subtypes (P=0.008). These data support the involvement of the HLA-C locus in modulating the risk of cervical neoplasia perhaps through its function as ligands for KIR, but functional studies are essential to confirm this hypothesis.

Keywords: Cervical neoplasia, HPV, HLA, KIR

Although the lifetime risk of contracting human papillomavirus (HPV) is 80% in the general population, most HPV infections are successfully resolved by the host immune system (Doorbar 2006). Even so, HPV infection is the most important risk factor for the development of intraepithelial lesions (CIN) and invasive carcinoma of the cervix (ICC) (IARC Working Group 1995). Moreover, persistent infection, which depends in part on the virus’ ability to subvert the immune system, is one of the critical steps in the progression of the disease (Koshiol et al. 2008). HPV DNA can be identified in almost all specimens of invasive cervical cancer and in the vast majority of cervical intraepithelial neoplasia grade 3 (CIN3) (Bosch and de Sanjose 2007).

There is convincing evidence that points to the role of the immune response in viral clearance including the increased incidence of HPV-related diseases in individuals with immune deficiency (Chaturvedi et al. 2009), and the presence of an intense inflammatory infiltrate in the vicinity of regressing genital warts (Coleman et al. 1994). HLA class I and class II proteins are central to the host immune responses to viral infections and other pathogens. They are the most polymorphic genes in the human genome and variations in the peptide binding groove influence antigenic specificity. Numerous studies have evaluated the association of HLA class I genes (HLA-A, HLA-B, and HLA-C) and class II genes (HLA-DQ and HLA-DR) with susceptibility to cervical cancer (Neuman et al. 2000; Wang et al. 2001, 2002a, b), and they point to the importance of HLA in the pathogenesis of cervical neoplasia. Further, loss of HLA class I occurs in >70% of primary cervical cancers (Koopman et al. 2000), enabling HPV-infected cells to escape detection by the immune system. Other immune system genes such as CD83 have also been implicated in susceptibility to cervical cancer (Zhang et al. 2007).

Natural killer (NK) cells are important elements of the innate immune system because they kill virus-infected cells and tumor cells. NK cells are regulated in part by activating and inhibitory killer immunoglobulin-like receptors (KIR), which recognize HLA class I molecules and convey either inhibitory or activating signals to NK cells. The interaction of inhibitory KIR (designated 2DL and 3DL) with specific HLA allotypes has been demonstrated (Long and Rajagopalan 2000; Reyburn et al. 1997).

Two case-control studies have examined the effects of variation at the KIR locus in women with CIN (Arnheim et al. 2005; Carrington et al. 2005). Carrington et al. found that specific inhibitory KIR/HLA ligand pairs were associated with decreased risk of developing cervical neoplasia, whereas the presence of the activating receptor KIR3DS1 resulted in increased risk of disease (Carrington et al. 2005). The study by Arnheim et al. indicated that the inhibitory allele KIR3DL1 associated with increased risk of CIN (although no mention is made of the grade of CIN), while the activating allele KIR3DS1 showed no association (Arnheim et al. 2005). These conflicting results led us to further examine the association of KIR and HLA genotypes with cervical cancer by analyzing a large population of affected women and family-based controls.

In order to assess whether KIR3DL1/KIR3DS1 and HLA class I genes influence susceptibility to the development of CIN3 and ICC, we genotyped for the presence/absence of KIR3DL1/3DS1 using PCR-SSP (Martin and Carrington 2008) and HLA-Bw/HLA-Cw group epitopes using sequencing analysis in cervical cancer trios (Table 1), which includes an affected woman and her biological parents. Due to the quality and/or quantity of available DNA, we were unable to perform full HLA-B and HLA-C allelic genotyping.

Table 1
Characteristics of the study subjects

HLA-Cw group 1, which serves as ligand for KIR2DL2/3, was significantly overtransmitted in the subset of women with ICC (P=0.04), while HLA-Cw group 2, which is the ligand for KIR2DL1, was under transmitted (Table 2). The significance of the association was further strengthened in the subgroup of women infected with HPV16- or HPV1618-associated HPV (P=0.008). There was no significant association of KIR3DL1/S1 or its HLA-Bw4 ligand with cervical cancer (Supplementary Tables 1 and 2). We next examined the compound genotypes composed of HLA-Bw, HLA-C group, and KIR. No additional effect of KIR and/or HLA-Bw in combination with HLA-C group was seen (data not shown).

Table 2
Association of HLA-Cw group 1 or 2 with CIN3 and ICC

Due to the association between HLA-C variation and cervical cancer, we next evaluated a recently described polymorphism in the region, rs9264942, which is 35 kb upstream of HLA-C and was shown to associate with HIV-1 viral load set point levels (Fellay et al. 2007). This SNP also associates with the level of HLA-C mRNA in immortalized B cell lines derived from individuals of European ancestry (Stranger et al. 2005; Stranger et al. 2007) as well as cell surface expression of HLA-C (Thomas et al. 2009). There was no significant association between rs9264942 genotype and ICC in our study (N=612 trios; p=0.52), suggesting that level of HLA-C expression may not modulate risk of ICC (Supplementary Table 3).

The association between HLA-Cw group 1 and increased risk of ICC in this study is in agreement with the previous study by Carrington et al. where HLA-Cw group 2 was significantly associated with a decreased risk of developing CIN3/cervical cancer (Carrington et al. 2005). Interestingly, an association study of HLA class I alleles across several case-control and cohort studies identified HLA-Cw*0202 (which is a group 2 allele) as protective in individuals with both high-grade Pap smears (OR 0.53, 95% CI 0.29–0.89) and low-grade Pap smears (OR 0.58, 95% CI 0.37–1.04) as compared with control subjects with normal cytologic cervical specimens (Wang et al. 2002a). Due to limited DNA resources, we were unable to perform full HLA-C allelic genotyping, and thus it was not possible to analyze individual HLA-C alleles in this study.

We replicated the HLA-Cw association in our family-based study using mostly women with invasive cervical cancer. The advantage of a family-based study is that it avoids false-positive results due to possible ethnic stratification that may affect the conventional case-control design (Cardon and Palmer 2003; Freedman et al. 2004). Furthermore, identification of adequate controls in a case-control study is problematic owing to the nearly ubiquitous, but heterogeneous, exposure to various HPV types and the ongoing risk of developing lesions with continued exposure. Family-based trios provide perfectly matched ethnic controls and obviate these other matching challenges. In addition, histologically confirmed tumor samples were available in our study, providing accurate diagnosis of stage as well as HPV type. While our cohort represents a relatively large data resource, it is not powered to find rather more subtle effects of variants on disease susceptibility. Power limitation may be responsible for the failure to replicate the HLA-B-KIR association in this study that was previously reported for CIN3 previously (Carrington et al. 2005). In general, very large sample sizes are needed to achieve adequate power to detect interaction effects, depending on their strength. In addition, accurate determination of KIR haplotypes even with family data is inherently problematic since it is not always possible to determine gene copy number and therefore transmission. The predominance of invasive cancer in the current study might also contribute to the lack of HLA-B and KIR association. Indeed, a cervical cancer screening study in China uncovered unique risk factor profiles for CIN1, 2, and 3, such as number of pregnancies (Belinson et al. 2008). Thus, many host factors might promote the heterogeneity of cervical disease.

It is unclear how activation of NK cells might promote the development of cervical cancer. Previous studies have suggested that genotypes that theoretically increase activation of NK cells are beneficial in viral infections such as HIV and HCV, whereas they increase the risk for autoimmunity and perhaps cancers that have an inflammatory component like cervical cancer (reviewed in Kulkarni et al. 2008). This suggests that the host response to HIV and HCV differ from the response to HPV. This finding is not surprising because highly active antiretroviral therapy for HIV does not reduce the incidence of CIN or cervical cancer in women infected with both viruses (De Vuyst et al. 2008). Moreover, genetic and functional studies have shown that KIR3DS1 protects against HIV infection even though it associates with increased susceptibility in cervical cancer (Carrington et al. 2008). Inflammation is an important response to infection, foreign elements such as tumor cells, and injury; however, on the flip side, chronic inflammation is also strongly associated with progression to certain cancers (de Visser et al. 2006). Indeed, inflammatory cells may be directly involved in malignant transformation and tumor progression by production of cytokines and other stimuli such as TNF-α, IL-6, and TGF-β that contribute to the proliferation and survival of tumor cells (Balkwill et al. 2005). The role of inflammation in the development of cervical cancer is not entirely understood. Thus, further work is needed to understand the role of inflammation and more specifically the role of NK cells and their receptors, in the development of cervical neoplasia.

The data presented here support the involvement of the HLA-C locus in modulating the risk of cervical neoplasia, as was implicated previously (Carrington et al. 2005). Overtransmission of HLA-Cw group 1, the ligands for KIR2DL2/3, in women with invasive cervical cancer, strengthens a model in which differential KIR-HLA-mediated interactions between effector cells and their targets alter the risk of cervical disease pathogenesis. However, functional studies are warranted in order to definitively define the role of KIR-HLA interactions in the pathogenesis of cervical cancer.

Supplementary Material

Acknowledgments

This work was supported by National Cancer Institute grants 5R01CA094141 and 5R01CA095713. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

Footnotes

Electronic supplementary material The online version of this article (doi:10.1007/s00251-010-0477-5) contains supplementary material, which is available to authorized users.

Contributor Information

Maureen P. Martin, Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, Inc. NCI-Frederick, Frederick, MD 21702, USA.

Ingrid B. Borecki, Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA.

Zhengyan Zhang, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO 63110, USA.

Loan Nguyen, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO 63110, USA.

Duanduan Ma, Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA.

Xiaojiang Gao, Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, Inc. NCI-Frederick, Frederick, MD 21702, USA.

Ying Qi, Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, Inc. NCI-Frederick, Frederick, MD 21702, USA.

Mary Carrington, Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, Inc. NCI-Frederick, Frederick, MD 21702, USA, Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, MA 02114, USA.

Janet S. Rader, Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO 63110, USA.

References

  • Arnheim L, Dillner J, Sanjeevi CB. A population-based cohort study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia. Tissue Antigens. 2005;65:252–259. [PubMed]
  • Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–217. [PubMed]
  • Belinson S, Smith JS, Myers E, Olshan A, Belinson J, Pretorius R, Qiao YL, Hartmann K. Descriptive evidence that risk profiles for cervical intraepithelial neoplasia 1, 2, and 3 are unique. Cancer Epidemiol Biomarkers Prev. 2008;17:2350–2355. [PubMed]
  • Bosch FX, de Sanjose S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers. 2007;23:213–227. [PubMed]
  • Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet. 2003;361:598–604. [PubMed]
  • Carrington M, Martin MP, van Bergen J. KIR-HLA intercourse in HIV disease. Trends Microbiol. 2008;16:620–627. [PubMed]
  • Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, Herrero R, Rodriguez AC, Kurman R, Mortel R, Schwartz P, Glass A, Hildesheim A. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med. 2005;201:1069–1075. [PMC free article] [PubMed]
  • Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst. 2009;101:1120–1130. [PMC free article] [PubMed]
  • Clayton D. A generalization of the transmission/disequilibrium test for uncertain-haplotype transmission. Am J Hum Genet. 1999;65:1170–1177. [PubMed]
  • Clayton D, Jones H. Transmission/disequilibrium tests for extended marker haplotypes. Am J Hum Genet. 1999;65:1161–1169. [PubMed]
  • Clayton J, Lonjou C. Allele and haplotype frequencies for HLA loci in various ethnic groups. In: Charron D, editor. Genetic Diversity of HLA. Functional and Medical Implication. Medical and Scientific International; Paris: 1997. pp. 668–820.
  • Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, Taylor-Robinson D, Stanley MA. Immunological events in regressing genital warts. Am J Clin Pathol. 1994;102:768–774. [PubMed]
  • de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24–37. [PubMed]
  • De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev. 2008;17:545–554. [PubMed]
  • Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110:525–541. [PubMed]
  • Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB. A whole-genome association study of major determinants for host control of HIV-1. Science. 2007;317:944–947. [PMC free article] [PubMed]
  • Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N, Gabriel SB, Topol EJ, Smoller JW, Pato CN, Pato MT, Petryshen TL, Kolonel LN, Lander ES, Sklar P, Henderson B, Hirschhorn JN, Altshuler D. Assessing the impact of population stratification on genetic association studies. Nat Genet. 2004;36:388–393. [PubMed]
  • IARC Working Group. Human papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 1995;64:1–378. [PubMed]
  • Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med. 2000;191:961–976. [PMC free article] [PubMed]
  • Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:123–137. [PMC free article] [PubMed]
  • Kulkarni S, Martin MP, Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol. 2008;20:343–352. [PubMed]
  • Li J, Gerhard DS, Zhang Z, Huettner PC, Wright J, Nguyen L, Lu D, Rader JS. Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus. J Clin Microbiol. 2003;41:5563–5571. [PMC free article] [PubMed]
  • Long EO, Rajagopalan S. HLA class I recognition by killer cell Ig-like receptors. Semin Immunol. 2000;12:101–108. [PubMed]
  • Martin MP, Carrington M. KIR locus polymorphisms: genotyping and disease association analysis. Methods Mol Biol. 2008;415:49–64. [PubMed]
  • Neuman RJ, Huettner PC, Li L, Mardis ER, Duffy BF, Wilson RK, Rader JS. Association between DQB1 and cervical cancer in patients with human papillomavirus and family controls. Obstet Gynecol. 2000;95:134–140. [PubMed]
  • Reyburn H, Mandelboim O, Vales-Gomez M, Sheu EG, Pazmany L, Davis DM, Strominger JL. Human NK cells: their ligands, receptors and functions. Immunol Rev. 1997;155:119–125. [PubMed]
  • Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, Lyle R, Hunt S, Kahl B, Antonarakis SE, Tavare S, Deloukas P, Dermitzakis ET. Genome-wide associations of gene expression variation in humans. PLoS Genet. 2005;1:e78. [PubMed]
  • Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE, Dunning M, Flicek P, Koller D, Montgomery S, Tavare S, Deloukas P, Dermitzakis ET. Population genomics of human gene expression. Nat Genet. 2007;39:1217–1224. [PMC free article] [PubMed]
  • Thomas R, Apps R, Qi Y, Gao X, Male V, O’HUigin C, O’Connor G, Ge D, Fellay J, Martin JN, Margolick J, Goedert JJ, Buchbinder S, Kirk GD, Martin MP, Telenti A, Deeks SG, Walker BD, Goldstein D, McVicar DW, Moffett A, Carrington M. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet. 2009;41:1290–1294. [PMC free article] [PubMed]
  • Wang SS, Hildesheim A, Gao X, Schiffman M, Herrero R, Bratti MC, Sherman ME, Barnes WA, Greenberg MD, McGowan L, Mortel R, Schwartz PE, Zaino RJ, Glass AG, Burk RD, Karacki P, Carrington M. Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J Infect Dis. 2002a;186:598–605. [PubMed]
  • Wang SS, Hildesheim A, Gao X, Schiffman M, Herrero R, Bratti MC, Sherman ME, Barnes WA, Greenberg MD, McGowan L, Mortel R, Schwartz PE, Zaino RJ, Glass AG, Burk RD, Karacki P, Carrington M. Human leukocyte antigen class I alleles and cervical neoplasia: no heterozygote advantage. Cancer Epidemiol Biomarkers Prev. 2002b;11:419–420. [PubMed]
  • Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, Sherman ME, Alfaro M, Hutchinson ML, Morales J, Lorincz A, Burk RD, Carrington M, Erlich HA, Apple RJ. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis. 2001;184:1310–1314. [PubMed]
  • Zhang Z, Borecki I, Nguyen L, Ma D, Smith K, Huettner PC, Mutch DG, Herzog TJ, Gibb RK, Powell MA, Grigsby PW, Massad LS, Hernandez E, Judson PL, Swisher EM, Crowder S, Li J, Gerhard DS, Rader JS. CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res. 2007;67:11202–11208. [PubMed]